Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Precancerous Conditions 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Cardiotoxicity 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Doxorubicin 11Razoxane 5Dexrazoxane 5Electrocardiography 4Echocardiography 4Cyclophosphamide 4Vincristine 3Trastuzumab 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Exercise 3Etoposide 3Carvedilol 3Radiotherapy 2Prednisone 2Methotrexate 2Magnetic Resonance Spectroscopy 2Bleomycin 2salicylhydroxamic acid 1oblimersen 1hydrocortisone hemisuccinate 1dapagliflozin 1Vascular Stiffness 1VAP-cyclo protocol 1Tablets 1Silymarin 1Reverse Transcriptase Polymerase Chain Reaction 1Resistance Training 1Pulse Wave Analysis 1Palliative Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cardiotoxicity × Fluorophotometry × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡